315-30-0 API Pharmaceutical Grade 99% Allopurinol Powder For Gout Suppressants

315-30-0 API Pharmaceutical Grade 99% Allopurinol Powder Gout Suppressants

The Introductction of Allopurinol

Allopurinol is a white or off-white crystalline powder, almost odorless, very slightly soluble in water or ethanol, insoluble in chloroform or ethe*, and soluble in sodium or potassium hydroxide.

Allopurinol is mainly used in the interictal and chronic phases of gout, for primary and secondary gout patients with excessive uric acid production, allergic or ineffective to uric acid-removing drugs, and those for whom uric acid-removing drugs are inappropriate, to control hyperuricemia, or in combination with uric acid-removing drugs to enhance the efficacy, especially for patients with severe gout stones and still good renal function.

Allopurinol and its metabolite oxypurinol prevent the deposition of uric acid stones by inhibiting the activity of xanthine oxidase (the latter converts hypoxanthine to xanthine, which in turn converts xanthine to uric acid), resulting in a decrease in uric acid production and a reduction of uric acid levels in the blood and urine to levels below solubility, thus contributing to the redissolution of gout nodules and uric acid crystals.

The Application & Function of Allopurinol

Indications
1, primary and secondary hyperuricemia, especially in those with excessive uric acid production, also for hyperuricemia in renal insufficiency;
2, for the treatment of gout, suitable for those with recurrent or chronic gout. Used for patients with gouty nephropathy to bring about symptom relief and to reduce the formation of uric acid stones in the kidneys;
3, gout stones;
4, for uric acid kidney stones and/or uric acid nephropathy.

Usage dosage
Oral: Initial dose of 50 mg/time, 1 to 2 times/day, may be increased by 50-100 mg/day to 200-300 mg/day in 2 to 3 doses per week. The maximum amount should not exceed 600 mg/day. Reduce the dosage for children as appropriate.

Adverse reactions
-Allergic reactions
The incidence of rash is 3% to 10%, which may be pruritic papules or urticaria, or may be blistering reactions. Other allergic reactions may occur in severe cases, such as exfoliative and purpuric lesions, erythema multiforme, etc. The drug should be discontinued as soon as skin lesions appear.

-Gastrointestinal tract
Diarrhea, nausea, vomiting, stomach pain or paroxysmal abdominal pain, etc. Occurrence 1 to 3%. Appropriate symptomatic treatment should be given in severe or persistent cases.

-Neurological system
Headache and dizziness are common, and peripheral neuritis symptoms such as numbness, tingling or pain in the hands and feet, and weakness are rare.

-Hematologic system
Granulocyte deficiency, anemia, thrombocytopenia, pancytopenia, and bone marrow suppression are rare and occur in <1% of cases.

-Other
There may be alopecia, fever, and lymph node enlargement, etc. Cataracts have been reported to be caused.

Other Name of Allopurinol:  

ACO
ALO
Adenock
NSC 101655
Allopurinol
ALLOPURINOL(P)
ALLOPURINOL,USP
AllopurinolBp2001
Hydroxypyrazolodpyrimidine
pyrazolo(3,4-d)pyrimidin-1-ol
4-Oxopyrazolo[3,4-d]pyrimidine
1H-Pyrazolo[3,4-d]pyrimidin-4-ol
4-Hydroxypyrazolo[3,4-d]pyrimidine
4-Hydroxypyrazolo(3,4-d)-pyrimidine
4-hydroxy-1H-pyrazolo(3,4-d)pyrimidine
1,2-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE(ALLOPURINOL)

The COA of Allopurinol

Product Name: Allopurinol

Batch No.: HNB20230528

Manufacture Date: May, 28^th, 2023      Analysis Date: May, 29^th, 2023        Expiry date: May, 27^th, 2025

Storage: Well-closed store in cool and dry place

Shelf life: 24 Months when properly stored.